08:43 AM EDT, 09/03/2025 (MT Newswires) -- Vaxcyte ( PCVX ) said Wednesday that its infant phase 2 study evaluating the VAX-31 vaccine in preventing invasive pneumococcal disease has progressed to the third and final stage.

The study advanced to the next stage after modifications to the protocol to add a new dose arm and discontinue enrollment in the low dose arm, the company said, adding that the middle- and high-dose arms are continuing as planned.

Vaxcyte ( PCVX ) said it expects to provide topline safety, tolerability, and immunogenicity data from the primary immunization series and the booster dose by the end of H1 of 2027.